Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-12-11
2007-12-11
Canella, Karen A. (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S588000, C514S591000, C514S596000, C514S597000, C514S619000, C514S620000, C514S647000, C514S660000, C514S670000, C514S672000, C514S673000, C514S716000, C514S717000, C514S718000, C514S719000, C514S721000, C514S722000, C514S747000, C514S749000, C514S751000
Reexamination Certificate
active
10308721
ABSTRACT:
Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.
REFERENCES:
patent: 4414928 (1983-11-01), Nakada
patent: 5040496 (1991-08-01), Plohberger et al.
patent: 7025021 (2006-04-01), Andersson et al.
patent: 7100550 (2006-09-01), Sheldon et al.
patent: WO 94/26260 (1994-11-01), None
patent: WO 97/36587 (1997-10-01), None
patent: WO03/013540 (2003-02-01), None
Messenger et al (Molecular and Cellular Biology, 1997, vol. 17, pp. 3229-3241).
Bollag Gideon
Lyons John F.
Canella Karen A.
Giotta Gregory
Onyx Pharmaceuticals, Inc
LandOfFree
RAF-MEK-ERK pathway inhibitors to treat cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RAF-MEK-ERK pathway inhibitors to treat cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RAF-MEK-ERK pathway inhibitors to treat cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3829194